MX2023012182A - Uso de anticuerpo en el tratamiento antitumoral. - Google Patents

Uso de anticuerpo en el tratamiento antitumoral.

Info

Publication number
MX2023012182A
MX2023012182A MX2023012182A MX2023012182A MX2023012182A MX 2023012182 A MX2023012182 A MX 2023012182A MX 2023012182 A MX2023012182 A MX 2023012182A MX 2023012182 A MX2023012182 A MX 2023012182A MX 2023012182 A MX2023012182 A MX 2023012182A
Authority
MX
Mexico
Prior art keywords
antibody
functional region
protein functional
tumor treatment
immunoglobulin
Prior art date
Application number
MX2023012182A
Other languages
English (en)
Inventor
Baiyong Li
Yu Xia
Zhongmin Maxwell Wang
Original Assignee
Akeso Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akeso Pharmaceuticals Inc filed Critical Akeso Pharmaceuticals Inc
Publication of MX2023012182A publication Critical patent/MX2023012182A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a un anticuerpo biespecífico contra CTLA4 y PD-1, en donde el anticuerpo se usa para tratar tumores, se administra en combinación con un anticuerpo monoclonal anti-VEGFR2 o un anticuerpo monoclonal anti-VEGF, y comprende una primera región funcional de proteína que se dirige a PD-1 y una segunda región funcional de proteína que se dirige a CTLA4, la primera región funcional de proteína que es una inmunoglobulina y la segunda región funcional de proteína que es un anticuerpo de cadena individual, o la primera región funcional de proteína que es un anticuerpo de cadena individual y la segunda región funcional de proteína que es una inmunoglobulina.
MX2023012182A 2021-04-14 2022-04-14 Uso de anticuerpo en el tratamiento antitumoral. MX2023012182A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202110404963 2021-04-14
PCT/CN2022/086870 WO2022218383A1 (zh) 2021-04-14 2022-04-14 抗体在抗肿瘤治疗中的用途

Publications (1)

Publication Number Publication Date
MX2023012182A true MX2023012182A (es) 2023-10-25

Family

ID=83574345

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023012182A MX2023012182A (es) 2021-04-14 2022-04-14 Uso de anticuerpo en el tratamiento antitumoral.

Country Status (11)

Country Link
US (1) US20240199741A1 (es)
EP (1) EP4324854A1 (es)
JP (1) JP2024515618A (es)
KR (1) KR20230171456A (es)
CN (1) CN115197325A (es)
AU (1) AU2022258365A1 (es)
BR (1) BR112023021177A2 (es)
CA (1) CA3213734A1 (es)
IL (1) IL307494A (es)
MX (1) MX2023012182A (es)
WO (1) WO2022218383A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104974253A (zh) * 2014-04-01 2015-10-14 上海中信国健药业股份有限公司 抗ctla-4/pd-1双特异性抗体、其制备方法及应用
CN106188296B (zh) * 2016-07-19 2018-05-08 康融东方（广东）医药有限公司 一类抗血管内皮生长因子受体vegfr2的单克隆抗体及其编码基因和应用
CN106967172B (zh) 2016-08-23 2019-01-08 康方药业有限公司 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途
WO2019179421A1 (en) * 2018-03-19 2019-09-26 Wuxi Biologics (Shanghai) Co., Ltd. Novel bispecific pd-1/ctla-4 antibody molecules
US20220411507A1 (en) * 2019-03-13 2022-12-29 Merck Sharp & Dohme Corp. Anti-cancer combination therapies comprising ctla-4 and pd-1 blocking agents
MX2022001321A (es) * 2019-08-02 2022-05-20 Akeso Pharmaceuticals Inc Anticuerpo biespecifico anti-ctla4/anti-pd-1 y uso del mismo.

Also Published As

Publication number Publication date
AU2022258365A1 (en) 2023-11-30
BR112023021177A2 (pt) 2023-12-19
CN115197325A (zh) 2022-10-18
JP2024515618A (ja) 2024-04-10
WO2022218383A1 (zh) 2022-10-20
EP4324854A1 (en) 2024-02-21
US20240199741A1 (en) 2024-06-20
KR20230171456A (ko) 2023-12-20
CA3213734A1 (en) 2022-10-20
IL307494A (en) 2023-12-01

Similar Documents

Publication Publication Date Title
Brischwein et al. MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors
US10081679B2 (en) Compositions comprising anti-CEACAM1 and anti-PD antibodies for cancer therapy
EA201891428A1 (ru) Комбинация антител к pd-1 и биспецифических антител к cd20/cd3 для лечения злокачественной опухоли
MX2022013163A (es) Anticuerpo contra nectin-4 y aplicacion del mismo.
EA202190088A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОГО НОВООБРАЗОВАНИЯ БИСПЕЦИФИЧЕСКИМИ АНТИТЕЛАМИ ПРОТИВ CD3xMUC16 И АНТИТЕЛАМИ ПРОТИВ PD-1
MX2020008446A (es) Metodos para el tratamiento contra el cancer mediante anticuerpos anti-pd-1 y anticuerpos anti-ctla4.
PH12021550041A1 (en) Anti-sortilin antibodies and methods of use thereof
MX2022014790A (es) Receptores de antígenos quiméricos específicos de p95her2 y usos de estos.
MX2022001260A (es) Anticuerpos anti-ms4a4a y metodos de uso de los mismos.
IL276675B2 (en) Anti-PD-1 antibodies and uses thereof
MX2022016039A (es) Anticuerpos anti-cd2.
MX2021010116A (es) Anticuerpo anti-pd-l1 y uso de este.
ZA202008095B (en) Humanized antibodies against psma
PH12020551187A1 (en) Bispecific antigen-binding molecules and methods of use
EA202192587A1 (ru) Антитела к cd73, антитела к pd-l1 и химиотерапия для лечения опухолей
Rösner et al. Epidermal growth factor receptor targeting IgG3 triggers complement-mediated lysis of decay-accelerating factor expressing tumor cells through the alternative pathway amplification loop
MX2022008421A (es) Anticuerpo anti-galectina-9 y usos del mismo.
MX2023012182A (es) Uso de anticuerpo en el tratamiento antitumoral.
MX2023001776A (es) Anticuerpos contra ilt2 y uso de los mismos.
MX2021015270A (es) Uso de moleculas biespecificas de union a antigeno que se unen a muc16 y cd3 en combinacion con la estimulacion conjunta de 4-1bb.
MX2020013450A (es) Materiales y métodos para tratar el cancer y los trastornos relacionados con el estrés.
RU2016127196A (ru) Способ лечения ран
MX2022006728A (es) Metodos y combinaciones para el tratamiento del cancer utilizando anticuerpos inhibidores de puntos de control inmunitario.
Vasilenko et al. Bispecific antibodies: formats and areas of application
MX2021015271A (es) Uso de moleculas biespecificas de union a antigeno que se unen a psma y cd3 en combinacion con la estimulacion conjunta de 4-1bb.